Ovid Therapeutics Inc.

Ovid Therapeutics Inc.

2.40
USD
-0.14
(-5.51%)
-0.28EPS
469.92MMarket Cap
Mar 15Next Earn

Total Valuation

USD

As of September 30, 2026, Ovid Therapeutics Inc. carries a market capitalization of 469.92M, placing it among publicly traded companies globally. Its enterprise value stands at 345.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap469.92M
Enterprise Value345.67M

Important Dates

Ovid Therapeutics Inc.'s next confirmed earnings release is scheduled for March 15, 2027.

Earnings Date3/15/2027

Share Statistics

As of September 30, 2026, Ovid Therapeutics Inc. has 188.72M shares outstanding.

Shares Outstanding188.72M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 265.27, and the price-to-book ratio stands at 2.37.

PS Ratio265.27
PB Ratio2.37
P/TBV Ratio2.37
P/FCF Ratio-6.66
P/OCF Ratio-6.66

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 238.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 345.67M versus a market cap of 469.92M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales238.23

Financial Position

As of September 30, 2026, Ovid Therapeutics Inc. maintains a current ratio of 11.97, meaning it holds 12.0x the short-term assets needed to cover near-term liabilities.

Current Ratio11.97
Quick Ratio11.52
Debt / Equity6.22
Debt / EBITDA-0.18

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, Ovid Therapeutics Inc. posted a negative return on equity (ROE) of -35.43, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -30.14, reflecting losses generated across the asset base. The company generates approximately 63,086.96 in revenue per employee across its workforce of 23.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-35.43
Return on Assets (ROA)-30.14
Revenue Per Employee63,086.96
Employee Count23.00

Stock Price Statistics

USD

As of the close on November 16, 2026, Ovid Therapeutics Inc.'s stock has gained approximately 83.91% over the past 52 weeks. The 50-day moving average sits at 2.50, while the 200-day moving average is 2.42.

52-Week Price Change83.91%
50-Day Moving Average2.50
200-Day Moving Average2.42

Income Statement

USD

Over the twelve months ended September 30, 2026, Ovid Therapeutics Inc. generated 1.45M in revenue and converted that into -43.11M in net income, yielding earnings per share of -0.28. EBITDA reached -68.12M, while operating income came in at -68.20M.

Revenue1.45M
Operating Income-68.20M
Pretax Income-43.11M
Net Income-43.11M
EBITDA-68.12M
EBIT-68.20M
Earnings Per Share (EPS)-0.28

Balance Sheet

USD

As of September 30, 2026, Ovid Therapeutics Inc. holds 136.60M in cash and equivalents against 12.35M in total debt, resulting in a net debt position of -13.81M. Total book value stands at 198.67M, with working capital of 130.10M providing operational flexibility.

Cash & Cash Equivalents136.60M
Total Debt12.35M
Net Debt-13.81M
Equity (Book Value)198.67M
Book Value Per Share1.05
Working Capital130.10M

Cash Flow

USD

Ovid Therapeutics Inc. produced -57.78M in operating cash flow over the twelve months ended September 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -57.78M - equivalent to -0.37 per share.

Operating Cash Flow-57.78M
Free Cash Flow-57.78M
FCF Per Share-0.37

Margins

These figures cover the twelve months ended September 30, 2026. The operating margin of -4,700.28 and net profit margin of -2,971.33 provide insight into operational efficiency.

Operating Margin-4,700.28
Pretax Margin-2,971.33
Profit Margin-2,971.33
EBITDA Margin-4,694.56

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -15.01: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -41.08, meaning Ovid Therapeutics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-41.08
FCF Yield-15.01

Scores

As of September 30, 2026, Ovid Therapeutics Inc. has an Altman Z-Score of 9.30, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score9.30